Myriad Genetics First Quarter 2025 Financial Earnings

05/06/2025 | 1:30pm PT / 4:30pm ET

Webcast Link
Register online

Events & Presentations

  • Myriad Genetics First Quarter 2025 Financial Earnings

    05/06/2025 | 1:30pm PDT / 4:30pm EDT

  • Leerink Global Healthcare Conference

    03/10/2025 | 11:20am PDT / 2:20pm EDT

  • Raymond James - 2025 RJ 46th Annual Institutional Investor Conference

    03/04/2025 | 1:00pm PST / 4:00pm EST

Financial Reports and Filings

Date Filing Title Downloads
04/15/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/15/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/09/2025 ARS An annual report to security holders RTF XLS PDF HTML XBRL
04/09/2025 DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") RTF XLS PDF HTML XBRL
04/09/2025 DEFA14A Additional proxy soliciting materials - definitive RTF XLS PDF HTML XBRL
03/26/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL

Latest News

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor Thumbnail

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Apr 30, 2025 | Products

Read more
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Thumbnail

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Apr 29, 2025 | Corporate | Financial

Read more
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting Thumbnail

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 25, 2025 | Products

Read more

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics